Approval · Notice of Compliance 37337 · 2026
STEQEYMA: Notice of Compliance 37337
Issued April 15, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37337
- Date
- April 15, 2026
- Company
- Celltrion Inc.Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Drug substance manufacturing process change
- Canadian reference product
- STELARA / STELARA I.V.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STEQEYMA | Not yet assigned | — |
| STEQEYMA I.V. | Not yet assigned | — |
Medicinal ingredients
- USTEKINUMAB 90 MG per ML
- USTEKINUMAB 45 MG per 0.5ML
- USTEKINUMAB 45 MG per SYR
- USTEKINUMAB 5 MG per ML